Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5806)
All Articles published online
|
Publishing Process of This Article
|
Nov 14, 2014 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, Giama NH, Therneau TM, Gores GJ, Roberts LR. Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol 2014; 20(42): 15750-15755 [PMID: 25400459 DOI: 10.3748/wjg.v20.i42.15750] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i42/15750.htm |
| Number | Citing Articles |
| 1 |
Jing Yang, Hang Yang, Ling Cao, Yuzhen Yin, Ying Shen, Wei Zhu. Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies. Medicine 2022; 101(49): e31799 doi: 10.1097/MD.0000000000031799
|
| 2 |
Maja Cigrovski Berkovic, Francesco Giovanardi, Anna Mrzljak, Quirino Lai. Prognostic role of metformin in diabetes mellitus type 2 patients with hepatocellular carcinoma: A systematic review and meta-analysis. World Journal of Diabetes 2023; 14(8): 1289-1300 doi: 10.4239/wjd.v14.i8.1289
Abstract(352) |
Core Tip(179) |
Full Article(HTML)(943)
|
Full Article with Cover (PDF)-3646K(44)
|
Full Article (Word)-1039K(21)
|
Audio-11949K(0)
|
Peer-Review Report-253K(32)
|
Answering Reviewers-78K(20)
|
Full Article (PDF)-3456K(129)
|
Full Article (XML)-147K(18)
|
Times Cited (0)
|
Total Visits (3130)
|
Open
|
| 3 |
Shereen El Shorbagy, Fouad abuTaleb, Hany A. Labib, Huda Ebian, Ola A. Harb, Mona Saeed Mohammed, Hanaa A. Rashied, Khaled A. Elbana, Rasha Haggag. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination. Journal of Gastrointestinal Cancer 2021; 52(1): 269 doi: 10.1007/s12029-020-00389-w
|
| 4 |
Miao-Ling Chen, Chun-Xue Wu, Jian-Bo Zhang, Hao Zhang, Yuan-Dong Sun, Shi-Lin Tian, Jian-Jun Han. Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.996228
|
| 5 |
Sofia de Oliveira, Ruth A. Houseright, Alyssa L. Graves, Netta Golenberg, Benjamin G. Korte, Veronika Miskolci, Anna Huttenlocher. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. Journal of Hepatology 2019; 70(4): 710 doi: 10.1016/j.jhep.2018.11.034
|
| 6 |
Aparna Bhat, Giada Sebastiani, Mamatha Bhat. Systematic review: Preventive and therapeutic applications of metformin in liver disease. World Journal of Hepatology 2015; 7(12): 1652-1659 doi: 10.4254/wjh.v7.i12.1652
|
| 7 |
Alexandra I Thompson, Kylie P Conroy, Neil C Henderson. Hepatic stellate cells: central modulators of hepatic carcinogenesis. BMC Gastroenterology 2015; 15(1) doi: 10.1186/s12876-015-0291-5
|
| 8 |
Lena Schulte, Bernhard Scheiner, Torsten Voigtländer, Sandra Koch, Nora Schweitzer, Silke Marhenke, Philipp Ivanyi, Michael P. Manns, Thomas Rodt, Jan B. Hinrichs, Arndt Weinmann, Matthias Pinter, Arndt Vogel, Martha M. Kirstein. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver International 2019; 39(4): 714 doi: 10.1111/liv.14048
|
| 9 |
Laurentia Gales, Leyla Forsea, Diana Mitrea, Irina Stefanica, Irina Stanculescu, Radu Mitrica, Mihai Georgescu, Oana Trifanescu, Rodica Anghel, Luiza Serbanescu. Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy. Medicina 2022; 58(9): 1239 doi: 10.3390/medicina58091239
|
| 10 |
Stephen Safe, Vijayalekshmi Nair, Keshav Karki. Metformin-induced anticancer activities: recent insights. Biological Chemistry 2018; 399(4): 321 doi: 10.1515/hsz-2017-0271
|
| 11 |
Ulfa Kholili, Alvin Hartanto Kurniawan, Choirina Winda, Ummi Maimunah, Poernomo Budi Setiawan. The Role of Metformin as Chemopreventive Strategies for Hepatocellular Carcinoma. Research Journal of Pharmacy and Technology 2023; : 377 doi: 10.52711/0974-360X.2023.00065
|
| 12 |
Yun‐Shan Wang, Lutao Du, Xingsi Liang, Peng Meng, Lei Bi, Yu‐li Wang, Chuanxin Wang, Bo Tang. Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine‐Monophosphate–Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice. Hepatology 2019; 69(4): 1614 doi: 10.1002/hep.30421
|
| 13 |
Woo Jin Jung, Sangmi Jang, Won Joon Choi, Jaewon Park, Gwang Hyeon Choi, Eun Sun Jang, Sook-Hyang Jeong, Won Seok Choi, Jae Hwan Lee, Chang Jin Yoon, Jin-Wook Kim. Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-18341-2
|
| 14 |
Young-Seok Seo, Yun-Jung Kim, Mi-Sook Kim, Kyung-Suk Suh, Sang Bum Kim, Chul Ju Han, Youn Joo Kim, Won Il Jang, Shin Hee Kang, Ha Jin Tchoe, Chan Mi Park, Ae Jung Jo, Hyo Jeong Kim, Jin A Choi, Hyung Jin Choi, Michael N. Polak, Min Jung Ko. Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection. Medicine 2016; 95(17): e3527 doi: 10.1097/MD.0000000000003527
|
| 15 |
Jian Zhou, Yang Ke, Xuefen Lei, Tiangen Wu, Yuehua Li, Tianhao Bao, Haoran Tang, Cheng Zhang, Xuesong Wu, Ge Wang, Jinze Li, Heng Zhang, Fan Ni, Zhengchen Ye, Lin Wang. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes. Annals of Hepatology 2020; 19(3): 320 doi: 10.1016/j.aohep.2019.11.008
|
| 16 |
Xue Jiang, Hor-Yue Tan, Shanshan Teng, Yau-Tuen Chan, Di Wang, Ning Wang. The Role of AMP-Activated Protein Kinase as a Potential Target of Treatment of Hepatocellular Carcinoma. Cancers 2019; 11(5): 647 doi: 10.3390/cancers11050647
|
| 17 |
Kaizhen Wang, Kuojun Zhang, Xiangyu Zhang, Dong Chen, Sheng Jiang. Recent Insights of Metformin on Hepatocellular Carcinoma (HCC). Mini-Reviews in Medicinal Chemistry 2023; 23(11): 1154 doi: 10.2174/1389557522666220623150717
|
| 18 |
Jonathan M. Hazlehurst, Conor Woods, Thomas Marjot, Jeremy F. Cobbold, Jeremy W. Tomlinson. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016; 65(8): 1096 doi: 10.1016/j.metabol.2016.01.001
|
| 19 |
Samuel O. Antwi, Zhuo Li, Kabir Mody, Lewis R. Roberts, Tushar Patel. Independent and Joint Use of Statins and Metformin by Elderly Patients With Diabetes and Overall Survival Following HCC Diagnosis. Journal of Clinical Gastroenterology 2020; 54(5): 468 doi: 10.1097/MCG.0000000000001182
|
| 20 |
Thanida Tangjarusritaratorn, Watip Tangjittipokin, Tada Kunavisarut. Incidence and Survival of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Cirrhosis Who Were Treated with and without Metformin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; : 1563 doi: 10.2147/DMSO.S295753
|
| 21 |
Xun Cao, Yaopan Wu, Jing Wang, Kuiyuan Liu, Xin Wang. The Effect of Metformin on Mortality Among Diabetic Cancer Patients: A Systematic Review and Meta-analysis. JNCI Cancer Spectrum 2017; 1(1) doi: 10.1093/jncics/pkx007
|
| 22 |
Christian Labenz, Vera Prenosil, Sandra Koch, Yvonne Huber, Jens U. Marquardt, Jörn M. Schattenberg, Peter R. Galle, Arndt Weinmann, Marcus-Alexander Wörns. Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Digestive Diseases 2018; 36(1): 78 doi: 10.1159/000477578
|
| 23 |
Cui-Song Luo, Yun Lin, Wei-Ping Zhou, Jun Shi. Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysis. European Journal of Gastroenterology & Hepatology 2020; 32(8): 1030 doi: 10.1097/MEG.0000000000001610
|
| 24 |
Wei-Ru Cho, Chih-Chi Wang, Meng-Yun Tsai, Chen-Kai Chou, Yueh-Wei Liu, Yi-Ju Wu, Ming-Tsung Lin, Kuang-Den Chen, Ching-Hui Chuang, Pao-Yuan Huang, Tsung-Hui Hu, Ming-Chao Tsai, Ming-Lung Yu. Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients. PLOS ONE 2021; 16(3): e0247231 doi: 10.1371/journal.pone.0247231
|
| 25 |
Rania Harati, Marc Vandamme, Benoit Blanchet, Christophe Bardin, Françoise Praz, Rifat Akram Hamoudi, Christèle Desbois-Mouthon. Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells. Molecular Pharmacology 2021; 100(1): 32 doi: 10.1124/molpharm.120.000223
|
| 26 |
Shu-Juan Ma, Yi-Xiang Zheng, Peng-Cheng Zhou, Yan-Ni Xiao, Hong-Zhuan Tan. Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. Oncotarget 2016; 7(40): 66202 doi: 10.18632/oncotarget.11033
|
| 27 |
Maria Corina Plaz Torres, Ariel Jaffe, Rachel Perry, Elisa Marabotto, Mario Strazzabosco, Edoardo G. Giannini. Diabetes medications and risk of HCC. Hepatology 2022; 76(6): 1880 doi: 10.1002/hep.32439
|
| 28 |
Stephanie Talamantes, Michela Lisjak, Eduardo H. Gilglioni, Camilo J. Llamoza-Torres, Bruno Ramos-Molina, Esteban N. Gurzov. Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma. JHEP Reports 2023; 5(9): 100811 doi: 10.1016/j.jhepr.2023.100811
|